Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
781-800 of 3,900 trials

JAK1 Inhibitor for Large Inflammatory Liver Adenomas

We are studying whether the oral medication baricitinib can help reduce the size of large inflammatory liver adenomas in patients. This trial also looks at the safety and effectiveness of this treatment compared to standard care.

Hepatocellular Adenoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Ofatumumab in Breast Milk: A Study for Lactating Women with MS

We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.

Multiple Sclerosis Relapse1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsNeurology

Advanced NSCLC: EXL-01 with Nivolumab

We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Peripheral Arterial Disease: New Imaging Agent Study

We are testing a new imaging agent in people with peripheral arterial occlusive disease and healthy volunteers. The goal is to understand its safety and how it distributes in the body.

Critical Limb IschaemiaPeripheral Arterial Occlusive Disease6-12 monthsSafety phase (I)CardiologyInternal Medicine

Triple Negative Breast Cancer: Capecitabine and Pembrolizumab Study

We are studying the effects of capecitabine combined with pembrolizumab in patients with triple negative breast cancer after surgery and chemotherapy. This trial aims to see if this combination improves survival rates compared to standard treatments.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Dostarlimab for Advanced Cancer with dMMR/MSI

We are studying whether the immunotherapy dostarlimab can help patients with advanced non-colorectal and non-endometrial cancers live longer compared to standard treatments. This trial focuses on those with specific genetic markers in their tumors.

dMMR/MSI Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Advanced Melanoma: IMC-F106C Plus Nivolumab

We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.

Advanced Melanoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Metastatic Non-Small Cell Lung Cancer: ONC-392 vs. Docetaxel

We are studying a new treatment, ONC-392, to see if it helps patients with metastatic non-small cell lung cancer who have progressed on immunotherapy. The goal is to compare its effectiveness and safety against the standard treatment, docetaxel.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Perianal Crohn’s Disease: FAPi-PET Imaging Study

We are exploring whether a new imaging method can help visualize and measure healing in fistulas for patients with perianal Crohn’s disease. This study may also help predict how well treatments are working.

Crohn's DiseaseFistulizing Crohn's Disease≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Brain Injury: Effects of Ketamine Treatment

We are studying whether adding ketamine to treatment helps lower the intensity of care needed for patients with acute brain injuries. We also want to see if it affects intracranial pressure.

Traumatic Brain Injury>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesNeurologyOtolaryngology

Hidradenitis Suppurativa: Bimekizumab for Teens

We are studying how the drug bimekizumab works and its safety for treating moderate to severe hidradenitis suppurativa in pubertal children and adolescents.

Hidradenitis SuppurativaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesAllergologyDermatology

Advanced Solid Tumors: STAR0602 Treatment

We are testing a new drug, STAR0602, to see if it can help stimulate the immune system in patients with advanced solid tumors that cannot be surgically removed. This study aims to explore its effects on tumors that have spread locally or to other parts of the body.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

TOS-358 for Adults with Solid Tumors

We are testing a new treatment called TOS-358 in adults with solid tumors. This study aims to understand how safe it is and how well it works.

Malignant Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Non-Hodgkin Lymphoma: Epcoritamab with Anti-Cancer Agents

We are studying the safety and tolerability of Epcoritamab combined with other anti-cancer medications for people with Non-Hodgkin Lymphoma. This trial aims to see how well this combination works and to find the best dose for future studies.

B-cell Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Influenza Vaccine Study for Hematological Cancer Patients

We are testing whether a high-dose flu vaccine works better than a standard dose in patients with hematological cancers. This study aims to improve vaccine effectiveness and understand immune responses in these patients.

Hematological Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInfectious Diseases

Advanced Solid Tumors: JNJ-87890387

We are testing a new treatment called JNJ-87890387 for patients with advanced solid tumors. The goal is to understand its safety and how it works in the body.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Cancer Treatment: Immune Markers and Side Effects

We are exploring blood markers in cancer patients to identify signs of side effects from checkpoint inhibitor treatments. This research may help improve safety and management of these therapies.

Solid Tumor>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Influenza Vaccine After Heart Attack: ELIMINATE Trial

We are studying whether an influenza vaccine can help reduce heart inflammation in people who have had a heart attack. This trial compares the vaccine to a placebo to see its effects on heart health.

Heart Attack>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCardiologyInfectious Diseases

Myotonic Dystrophy Type 1: ATX-01 Treatment Study

We are evaluating the safety and effects of ATX-01 in adults with myotonic dystrophy type 1. The study aims to see how it impacts muscle function and daily living activities.

Myotonic Dystrophy6-12 monthsSafety phase (I)Post-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurology

Dapagliflozin for Patients Undergoing Heart Bypass Surgery

We are studying whether dapagliflozin can help prevent new heart rhythm problems and kidney issues in patients awaiting coronary artery bypass surgery. This research aims to improve recovery and overall outcomes after surgery.

Atrial Fibrillation and Acute Kidney Injury after CABG3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyInternal MedicineNephrology